The Journal of Experimental Medicine
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 30 July 2001. doi:10.1084/jem.194.3.255
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engels, N.
Right arrow Articles by Wienands, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engels, N.
Right arrow Articles by Wienands, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/8/255/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 3, August 6, 2001 255-264

Original Article

Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Employs the SLP-65 Signaling Module

Niklas Engelsa, Mark Merchantb, Rajita Pappuc, Andrew C. Chanc, Richard Longneckerb, and Jürgen Wienandsa
a Department of Biochemistry I, University of Bielefeld, Bielefeld D-33615, Germany
b Department of Microbiology and Immunology, Northwestern University Medical School, Chicago, IL 60611
c Center for Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110

Correspondence to: Jürgen Wienands, Department of Biochemistry I, University of Bielefeld, Universitätsstrasse 25, Bielefeld D-33615, Germany. Tel:49-521-106-2081 Fax:49-521-106-8105 E-mail:j.wienands{at}uni-bielefeld.de.

In latently infected B lymphocytes, the Epstein-Barr virus (EBV) suppresses signal transduction from the antigen receptor through expression of the integral latent membrane protein 2A (LMP2A). At the same time, LMP2A triggers B cell survival by a yet uncharacterized maintenance signal that is normally provided by the antigen receptor. The molecular mechanisms are unknown as LMP2A-regulated signaling cascades have not been described so far. Using a novel mouse model we have identified the intracellular adaptor protein Src homology 2 (SH2) domain–containing leukocyte protein (SLP)-65 as a critical downstream effector of LMP2A in vivo. Biochemical analysis of the underlying signaling pathways revealed that EBV infection causes constitutive tyrosine phosphorylation of one of the two SLP-65 isoforms and complex formation between SLP-65 and the protooncoprotein CrkL (CT10 regulator of kinase like). This leads to antigen receptor-independent phosphorylation of Cbl (Casitas B lineage lymphoma) and C3G. In contrast, phospholipase C-{gamma}2 (PLC-{gamma}2) activation is completely blocked. Our data show that in order to establish a latent EBV infection, LMP2A selectively activates or represses SLP-65–regulated signaling pathways.

Key Words: B lymphocytes, Epstein-Barr virus, antigen receptor, SLP-65, signal transduction


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS